Schellong, Sebastian and Ageno, Walter and Casella, Ivan B. and Chee, Kok Han and Schulman, Sam and Singer, Daniel E. and Desch, Marc and Tang, Wenbo and Voccia, Isabelle and Zint, Kristina and Goldhaber, Samuel Z. (2022) Profile of patients with isolated distal deep vein thrombosis versus proximal deep vein thrombosis or pulmonary embolism: RE-COVERY DVT/PE study. Seminars in Thrombosis and Hemostasis, 48 (04). pp. 446-458. ISSN 0094-6176, DOI https://doi.org/10.1055/s-0041-1729169.
Full text not available from this repository.Abstract
Isolated distal deep vein thrombosis (IDDVT) is presumed to be more benign than proximal DVT (PDVT) or pulmonary embolism (PE), suggesting a need for different management approaches. This subgroup analysis of the RE-COVERY DVT/PE global, observational study investigated patient characteristics, hospitalization details, and anticoagulant therapy in patients with IDDVT in real-world settings in 34 countries enrolled from January 2016 to May 2017. Data were analyzed descriptively according to the type and location of the index venous thromboembolism (VTE): IDDVT, PDVTdistal DVT (DDVT), and PE +/- DVT. Of the 6,095 eligible patients, 323 with DVT located outside the lower limb and no PE were excluded. Of the remaining 5,772 patients, 17.6% had IDDVT, 39.9% had PDVT +/- DDVT, and 42.5% had PE +/- DVT. IDDVT patients were younger and had fewer risk factors for VTE than the other groups. Other comorbidities were less frequent in the IDDVT group, except for varicose veins, superficial thrombophlebitis, and venous insufficiency. IDDVT patients were less likely to be diagnosed in an emergency department (22.3 vs. 29.7% for PDVT +/- DDVT and 45.4% for PE +/- DVT) or hospitalized for VTE (29.2 vs. 48.5% for PDVT +/- DDVT and 75.0% for PE +/- DVT). At hospital discharge or 14 days after diagnosis (whichever was later), non-vitamin K antagonist oral anticoagulants were the most commonly used anticoagulants (55.6% for IDDVT, 54.7% for PDVT +/- DDVT, and 52.8% for PE +/- DVT). Although differences in patient characteristics, risk factors, and clinical management were identified, anticoagulant treatment of IDDVT was almost equal to that of PDVT or PE. Prospective studies should investigate whether, in a global perspective, this is an appropriate use of anticoagulants. Trial registration number ClinicalTrials.gov NCT02596230.
| Item Type: | Article |
|---|---|
| Funders: | Thrombosis Research Institute, National Heart, Lung, and Blood Institute, Daiichi Sankyo Europe |
| Uncontrolled Keywords: | Anticoagulants; Direct thrombin inhibitors; Distal deep vein thrombosis; Pulmonary embolism; Venous thrombosis |
| Subjects: | R Medicine > R Medicine (General) |
| Divisions: | Faculty of Medicine > Medicine Department |
| Depositing User: | Ms. Juhaida Abd Rahim |
| Date Deposited: | 03 Jun 2025 07:44 |
| Last Modified: | 03 Jun 2025 07:44 |
| URI: | http://eprints.um.edu.my/id/eprint/41827 |
Actions (login required)
 |
View Item |
